Crunch Time For Aerie At EMA
An EU Marketing Recommendation Could Be In Store For New Glaucoma Treatment
Executive Summary
Aerie is already exploring its pricing strategy for Roclanda as the European Medicines Agency this week decides whether the intraocular pressure treatment should be approved in Europe.
You may also be interested in...
Phesgo & Roclanda Among New Winners At EMA
The European Medicines Agency this week recommended that five new products be granted EU marketing approval.
Hits, Misses & Key Firsts For EMA’s PRIME Scheme
The rate at which investigational drugs were accepted onto the European Medicines Agency’s priority medicines scheme dropped in 2021. Meanwhile, more much-needed treatments that had been developed under the scheme went on to win EU marketing approval.
First Academic Sponsor On EMA’s PRIME Pledges Cheaper CAR-Ts
An investigational CAR T-cell therapy that hospital researchers in Spain believe they could produce at a third of the price of commercially available CART19 products has been accepted onto the European Medicines Agency's priority medicines scheme.